Report in English with a Dutch summary (KCE reports 63A)
Report in English with a Dutch summary (KCE reports 63A)
Report in English with a Dutch summary (KCE reports 63A)
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>KCE</strong> <strong>reports</strong> 63 Breast Cancer 39<br />
81. The Breast Cancer Disease Site Group, Adjuvant Systemic Therapy for Node-negative Breast<br />
Cancer., C.C. Ontario, Editor. 2003, Cancer Care Ontario: Toronto.<br />
82. Arriagada, R., et al., Results of two randomized trials evaluat<strong>in</strong>g adjuvant anthracycl<strong>in</strong>e-based<br />
chemotherapy <strong>in</strong> 1146 patients <strong>with</strong> early breast cancer. Acta Oncologica, 2005. 44(5): p. 458-66.<br />
83. Hutch<strong>in</strong>s, L.F., et al., Randomized, controlled trial of cyclophosphamide, methotrexate, and<br />
fluorouracil versus cyclophosphamide, doxorubic<strong>in</strong>, and fluorouracil <strong>with</strong> and <strong>with</strong>out tamoxifen<br />
for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.<br />
Journal of Cl<strong>in</strong>ical Oncology, 2005. 23(33): p. 8313-21.<br />
84. Lev<strong>in</strong>e, M.N., et al., Randomized trial compar<strong>in</strong>g cyclophosphamide, epirubic<strong>in</strong>, and fluorouracil<br />
<strong>with</strong> cyclophosphamide, methotrexate, and fluorouracil <strong>in</strong> premenopausal women <strong>with</strong> nodepositive<br />
breast cancer: update of National Cancer Institute of Canada Cl<strong>in</strong>ical Trials Group Trial<br />
MA5. Journal of Cl<strong>in</strong>ical Oncology, 2005. 23(22): p. 5166-70.<br />
85. Bria, E., et al., Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis<br />
of 15,500 patients. Cancer, 2006. 106(11): p. 2337-44.<br />
86. Mauri, D., N. Pavlidis, and J.P.A. Ioannidis, Neoadjuvant versus adjuvant systemic treatment <strong>in</strong><br />
breast cancer: a meta-analysis.[see comment]. Journal of the National Cancer Institute, 2005.<br />
97(3): p. 188-94.<br />
87. Farquhar, C., et al., High dose chemotherapy and autologous bone marrow or stem cell<br />
transplantation versus conventional chemotherapy for women <strong>with</strong> early poor prognosis breast<br />
cancer. Cochrane Database Syst Rev, 2005(3): p. CD003139.<br />
88. Early Breast Cancer Trialists' Collaborative, G., Effects of chemotherapy and hormonal therapy for<br />
early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.[see<br />
comment]. Lancet, 2005. 365(9472): p. 1687-717.<br />
89. Sharma, R., J. Beith, and A. Hamilton, Systematic review of LHRH agonists for the adjuvant<br />
treatment of early breast cancer. Breast, 2005. 14(3): p. 181-91.<br />
90. Baum, M., et al., Adjuvant goserel<strong>in</strong> <strong>in</strong> pre-menopausal patients <strong>with</strong> early breast cancer: Results<br />
from the ZIPP study. European Journal of Cancer, 2006. 42(7): p. 895-904.<br />
91. Davidson, N.E., et al., Chemoendocr<strong>in</strong>e therapy for premenopausal women <strong>with</strong> axillary lymph<br />
node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101<br />
(E5188).[see comment]. Journal of Cl<strong>in</strong>ical Oncology, 2005. 23(25): p. 5973-82.<br />
92. De Placido, S., et al., A randomised factorial trial of sequential doxorubic<strong>in</strong> and CMF vs CMF and<br />
chemotherapy alone vs chemotherapy followed by goserel<strong>in</strong> plus tamoxifen as adjuvant treatment<br />
of node-positive breast cancer. British Journal of Cancer, 2005. 92(3): p. 467-74.<br />
93. Ovarian ablation or suppression <strong>in</strong> premenopausal early breast cancer: results from the<br />
<strong>in</strong>ternational adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl<br />
Cancer Inst, 2007. 99(7): p. 516-25.<br />
94. Mauri, D., et al., Survival <strong>with</strong> aromatase <strong>in</strong>hibitors and <strong>in</strong>activators versus standard hormonal<br />
therapy <strong>in</strong> advanced breast cancer: meta-analysis.[see comment]. Journal of the National Cancer<br />
Institute, 2006. 98(18): p. 1285-91.<br />
95. Bria, E., et al., Early switch <strong>with</strong> aromatase <strong>in</strong>hibitors as adjuvant hormonal therapy for<br />
postmenopausal breast cancer: pooled-analysis of 8794 patients. Cancer Treatment Reviews, 2006.<br />
32(5): p. 325-32.<br />
96. Eisen, A., et al., The Role of Aromatase Inhibitors <strong>in</strong> Adjuvant Therapy for Postmenopausal<br />
Women <strong>with</strong> Hormone Receptor-positive Breast Cancer. Evidence-based Series #1-18., C.C.<br />
Ontario, Editor. 2005, Cancer Care Ontario: Toronto.<br />
97. Goss, P.E., Prevent<strong>in</strong>g relapse beyond 5 years: the MA.17 extended adjuvant trial. Sem<strong>in</strong>ars <strong>in</strong><br />
Oncology, 2006. 33(2 Suppl 7): p. S8-12.<br />
98. Kim, R., et al., Rationale for sequential tamoxifen and anticancer drugs <strong>in</strong> adjuvant sett<strong>in</strong>g for<br />
patients <strong>with</strong> node- and receptor-positive breast cancer. Int J Oncol, 2005. 26(4): p. 1025-31.<br />
99. Huybrechts, M., et al., Trastuzumab bij vroegtijdige stadia van borstkanker, <strong>in</strong> <strong>KCE</strong> <strong>reports</strong>. 2006,<br />
Federaal Kenniscentrum voor de gezondheidszorg (<strong>KCE</strong>): Brussel.
Change language